经鼻高流量氧疗与无创通气治疗成人急性高碳酸血症性呼吸衰竭:随机试验的系统评价与Meta分析
该系统评价与Meta分析检索EMBASE、MEDLINE和Cochrane图书馆至2021年10月,纳入8项RCT共528例成人急性高碳酸血症性呼吸衰竭患者,比较HFNC与NIV。主要终点死亡率无显著差异(RR 0.86,95%CI 0.48-1.56,低确定性),气管插管(RR 0.80,95%CI 0.46-1.39,低确定性)、住院时长(MD -0.82天,95%CI -1.83-0.20,高确定性)及PaCO2变化(MD -1.87 mmHg,95%CI -5.34-1.60,中等确定性)亦无显著差异。作者认为,因不精确性和研究异质性,现有证据尚不足以判定HFNC优于、劣于或等效于NIV,需进一步研究。
要点
- 8项RCT共528例成人急性高碳酸血症性呼吸衰竭患者,HFNC与NIV比较,死亡率无显著差异(RR 0.86,95%CI 0.48-1.56,低确定性)。
- 气管插管风险无显著差异(RR 0.80,95%CI 0.46-1.39,低确定性)。
- 住院时长无显著差异(MD -0.82天,95%CI -1.83-0.20,高确定性)。
- PaCO2变化无显著差异(MD -1.87 mmHg,95%CI -5.34-1.60,中等确定性)。
- 作者认为现有证据因不精确性和研究异质性受限,尚不能判定HFNC优于、劣于或等效于NIV,需进一步研究。
适用人群与场景
- 成人急性高碳酸血症性呼吸衰竭患者,来自8项随机对照试验(n=528)。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入8项随机对照试验(RCT),共528例成人急性高碳酸血症性呼吸衰竭患者;检索EMBASE、MEDLINE和Cochrane图书馆自建库至2021年10月。
- 主要终点死亡率:HFNC vs NIV的RR 0.86(95%CI 0.48-1.56,低确定性),无显著差异。
- 次要终点气管插管:RR 0.80(95%CI 0.46-1.39,低确定性),无显著差异。
- 次要终点住院时长:MD -0.82天(95%CI -1.83-0.20,高确定性),无显著差异。
- 次要终点PaCO2变化:MD -1.87 mmHg(95%CI -5.34-1.60,中等确定性),无显著差异。
- 合并方法:二分类结局计算合并相对危险度(RR),连续结局计算均数差(MD),均使用随机效应模型,并报告95%置信区间(CI)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入8项随机对照试验(RCT)。
- 证据确定性:死亡率低确定性,气管插管低确定性,住院时长高确定性,PaCO2变化中等确定性。
- 局限:作者指出因不精确性和研究异质性,现有证据受限,需进一步研究以更好理解HFNC在该人群中的效应。
对床旁实践的改变
- 作者认为,当前证据尚不能判定HFNC优于、劣于或等效于NIV用于成人急性高碳酸血症性呼吸衰竭患者,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Non-invasive ventilation (NIV) with bi-level positive pressure ventilation is a first-line intervention for selected patients with acute hypercapnic respiratory failure. Compared to conventional oxygen therapy, NIV may reduce endotracheal intubation, death, and intensive care unit length of stay (LOS), but its use is often limited by patient tolerance and treatment failure. High-flow nasal cannula (HFNC) is a potential alternative treatment in this patient population and may be better tolerated.
RESEARCH QUESTION: For patients presenting with acute hypercapnic respiratory failure, is HFNC an effective alternative to NIV in reducing the need for intubation?
METHODS: We searched EMBASE, MEDLINE, and the Cochrane library from database inception through to October 2021 for randomized clinical trials (RCT) of adults with acute hypercapnic respiratory failure assigned to receive HFNC or NIV. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. We calculated pooled relative risks (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with corresponding 95% confidence intervals (CI) using a random-effects model.
RESULTS: We included eight RCTs (n = 528) in the final analysis. The use of HFNC compared to NIV did not reduce the risk of our primary outcome of mortality (RR 0.86, 95% CI 0.48-1.56, low certainty), or our secondary outcomes including endotracheal intubation (RR 0.80, 95% CI 0.46-1.39, low certainty), or hospital LOS (MD - 0.82 days, 95% CI - 1.83-0.20, high certainty). There was no difference in change in partial pressure of carbon dioxide between groups (MD - 1.87 mmHg, 95% CI - 5.34-1.60, moderate certainty).
INTERPRETATION: The current body of evidence is limited in determining whether HFNC may be either superior, inferior, or equivalent to NIV for patients with acute hypercapnic respiratory failure given imprecision and study heterogeneity. Further studies are needed to better understand the effect of HFNC on this population.
参考来源
- Ovtcharenko N, Ho E, Alhazzani W, et al. High-flow nasal cannula versus non-invasive ventilation for acute hypercapnic respiratory failure in adults: a systematic review and meta-analysis of randomized trials. Crit Care. 2022. PMID: 36352457. doi:10.1186/s13054-022-04218-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。